Read more

May 23, 2021
2 min watch
Save

VIDEO: Psoriasis itself, treatment 'does not seem' to impact COVID-19 risks

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

In this video, Joel M. Gelfand, MD, MSCE, professor of dermatology and epidemiology at the University of Pennsylvania Perelman School of Medicine, addresses concerns that treatments for psoriatic disease could increase patients’ risk for COVID-19 infection or severe illness.

Gelfand discussed these and other COVID-19-related concerns among patients with psoriasis during a presentation at AAD VMX 2021.

He explained that based on research published in the last year, “it does not seem that psoriasis itself or the treatments we use in psoriatic disease meaningfully impact the risk for getting this virus or having worse outcomes from the virus.”

According to Gelfand, “what really drives risks is the major comorbidities people with psoriasis often have,” such as obesity, diabetes and CVD.